Fmr LLC Boosts Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Fmr LLC grew its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 4.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,916,494 shares of the company’s stock after buying an additional 129,300 shares during the period. Fmr LLC owned 2.57% of Centessa Pharmaceuticals worth $46,635,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC increased its position in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP raised its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals during the second quarter worth approximately $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CNTA shares. Jefferies Financial Group lifted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets upped their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Guggenheim raised their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Oppenheimer reissued an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $18.67 on Friday. The company has a market cap of $2.46 billion, a PE ratio of -12.20 and a beta of 1.52. Centessa Pharmaceuticals plc has a 12 month low of $6.15 and a 12 month high of $18.77. The company has a fifty day moving average price of $16.41 and a two-hundred day moving average price of $12.96. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the transaction, the chief executive officer now directly owns 776,924 shares of the company’s stock, valued at $12,834,784.48. This represents a 18.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the sale, the insider now directly owns 183,266 shares in the company, valued at $3,236,477.56. The trade was a 5.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 462,624 shares of company stock worth $7,763,698 in the last three months. 11.59% of the stock is owned by insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.